Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (‘Progenics’), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced that at a special meeting of its stockholders held earlier Tuesday, Progenics’ stockholders voted to approve its proposed merger with Lantheus Holdings, Inc. (‘Lantheus’), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, by adopting the previously announced Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the ‘Merger Agreement’), by and among Progenics, Lantheus and Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus (‘Merger Sub’), pursuant to which Merger Sub will be merged with and into Progenics (the ‘merger’), with Progenics surviving the merger as a wholly-owned subsidiary of Lantheus.
Read the full article: Progenics Stockholders Approve Merger with Lantheus //
Source: https://www.globenewswire.com/news-release/2020/06/16/2049136/0/en/Progenics-Stockholders-Approve-Merger-with-Lantheus.html